BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37953364)

  • 1. The role of radiotherapy in tumor immunity and the potential of PET/CT in detecting the expression of PD-1/PD-L1.
    Shen LF; Fu ZM; Zhou SH
    Jpn J Radiol; 2024 Apr; 42(4):347-353. PubMed ID: 37953364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for PD-L1 expression in non-small cell lung cancer: A systematic review and meta-analysis.
    Seol HY; Kim YS; Kim SJ
    Thorac Cancer; 2020 Nov; 11(11):3260-3268. PubMed ID: 32951338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Value of
    Vekens K; Everaert H; Neyns B; Ilsen B; Decoster L
    Clin Lung Cancer; 2021 Sep; 22(5):432-440. PubMed ID: 33879398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma.
    Kasahara N; Kaira K; Bao P; Higuchi T; Arisaka Y; Erkhem-Ochir B; Sunaga N; Ohtaki Y; Yajima T; Kosaka T; Oyama T; Yokobori T; Asao T; Nishiyama M; Tsushima Y; Kuwano H; Shimizu K; Mogi A
    Lung Cancer; 2018 May; 119():71-77. PubMed ID: 29656756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on
    Takada K; Toyokawa G; Okamoto T; Baba S; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Honda H; Oda Y; Maehara Y
    Cancer Med; 2017 Nov; 6(11):2552-2561. PubMed ID: 28980429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Construction of A Nomogram Prediction Model for PD-L1 Expression 
in Non-small Cell Lung Cancer Based on 18F-FDG PET/CT Metabolic Parameters].
    Hao L; Wang L; Zhang M; Yan J; Zhang F
    Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):833-842. PubMed ID: 38061885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel [
    Puyalto A; Rodríguez-Remírez M; López I; Iribarren F; Simón JA; Ecay M; Collantes M; Vilalta-Lacarra A; Francisco-Cruz A; Solórzano JL; Sandiego S; Peñuelas I; Calvo A; Ajona D; Gil-Bazo I
    Front Immunol; 2023; 14():1272570. PubMed ID: 37841258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations of Tumor PD-1 Ligands, Immunohistochemical Studies, and Textural Features in
    Chen RY; Lin YC; Shen WC; Hsieh TC; Yen KY; Chen SW; Kao CH
    Sci Rep; 2018 Jan; 8(1):105. PubMed ID: 29311707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of
    Kaira K; Kuji I; Kagamu H
    Cancer Imaging; 2021 Jan; 21(1):11. PubMed ID: 33441183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma.
    Kaira K; Shimizu K; Kitahara S; Yajima T; Atsumi J; Kosaka T; Ohtaki Y; Higuchi T; Oyama T; Asao T; Mogi A
    Eur J Cancer; 2018 Sep; 101():181-190. PubMed ID: 30077123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insight on the correlation of metabolic status on
    Wang Y; Zhao N; Wu Z; Pan N; Shen X; Liu T; Wei F; You J; Xu W; Ren X
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1127-1136. PubMed ID: 31502013
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Kimura Y; Sasada S; Emi A; Masumoto N; Kadoya T; Arihiro K; Okada M
    Anticancer Res; 2023 Jan; 43(1):127-136. PubMed ID: 36585209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor immunity is related to
    Imai H; Kaira K; Hashimoto K; Nitanda H; Taguchi R; Yanagihara A; Umesaki T; Yamaguchi O; Mouri A; Kawasaki T; Yasuda M; Kobayashi K; Sakaguchi H; Kuji I; Kagamu H
    Cancer Med; 2021 Sep; 10(18):6317-6326. PubMed ID: 34363337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([
    Hughes DJ; Josephides E; O'Shea R; Manickavasagar T; Horst C; Hunter S; Tanière P; Nonaka D; Van Hemelrijck M; Spicer J; Goh V; Bille A; Karapanagiotou E; Cook GJR
    Eur Radiol; 2024 Feb; ():. PubMed ID: 38388716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic test accuracy of
    Seol HY; Kim YS; Kim SJ
    Clin Radiol; 2021 Nov; 76(11):863.e19-863.e25. PubMed ID: 34261597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between the expression of PD-1/PD-L1 and
    Chen R; Zhou X; Liu J; Huang G
    Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):848-854. PubMed ID: 30627815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between PD-L1 expression and
    Choi YJ; Jo K; Hwang SH; Jeong Y; Lee JY; Kim S; Kim SW; Kim YT; Kang WJ
    Ann Nucl Med; 2021 Apr; 35(4):415-420. PubMed ID: 33656683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Negative Correlation Between
    Wu L; Liu J; Wang S; Bai M; Wu M; Gao Z; Li J; Yu J; Liu J; Meng X
    Front Endocrinol (Lausanne); 2022; 13():913631. PubMed ID: 35846323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between SUVmax on 18F-FDG PET and PD-L1 expression in hepatocellular carcinoma.
    Zhou X; Hu Y; Sun H; Chen R; Huang G; Liu J
    Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3107-3115. PubMed ID: 37147479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers.
    Liberini V; Laudicella R; Capozza M; Huellner MW; Burger IA; Baldari S; Terreno E; Deandreis D
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33920423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.